DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Infographic

  • Biosimilars Insights Infographic

    Global Biosimilars Pathways and Clinical Development Activity Since the introduction of the first biosimilar guidelines in 2005, the biosimilars field has continued to evolve. Over fifty biosimilars...

  • Mapping the Clinical Path in Rheumatoid Arthritis With Real World Data

      Real World Data has the potential to boost brand performance, fine-tune commercial strategy, tease out subtle market nuances, and unlock hidden opportunities. The below infographic utilizes US...

  • Regenerative Medicine 2017

    Both gene and cell therapies do not yet have a foothold in the market but the potential for a market explosion is not only possible, but well on its way to becoming inevitable. The following...

  • Biosimilar Substitution by State

      Some states don’t have substitution laws--find out which ones. Pharma and payers often disagree over how U.S. states should address substitutions of low-cost versions of biologic drugs. Many...

  • States advance telemedicine capabilities

    Patients are increasingly demanding instantaneous access to healthcare services, particularly as they become more engaged in real-time communication through the use of smart-phones and social media...

  • TCT 2017 Conference Coverage

    The Transcatheter Cardiovascular Therapeutics (TCT) conference is the world’s largest and most important educational meeting specializing in interventional cardiovascular medicine. For over 25 years...

  • Top 5 States for Value-Based Contracting

      As more and more integrated delivery networks embrace value-based care, the pharmaceutical companies they contract with for prescription drugs also are pivoting away from pricing models that...

  • The Top 10 Blockbuster Drugs by 2025

      DRG research indicates that about 200 launches are expected during 2017-2019, of which approximately 14% are forecast to become blockbusters. The new launches in this period will garner sales...

  • Understanding US healthcare coverage: Impacts from Medicaid expansion

      Our newest infographic displays Medicaid expansion to date across the United States, leveraging covered lives data from DRG’s Managed Market Surveyor platform with a highlight on Ohio’s...

1-9 of 21